Elanco Animal Health (NYSE:ELAN) Releases FY 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 1.030-1.090 for the period, compared to the consensus estimate of 1.030. The company issued revenue guidance of $5.0 billion-$5.1 billion, compared to the consensus revenue estimate of $5.0 billion. Elanco Animal Health also updated its Q2 2026 guidance to 0.250-0.285 EPS.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of research analyst reports. Morgan Stanley increased their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 18th. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $24.00 to $30.00 in a research note on Thursday, January 22nd. Leerink Partners lifted their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a research note on Tuesday, February 24th. Finally, KeyCorp lifted their target price on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.90.

Elanco Animal Health Trading Up 13.3%

Elanco Animal Health stock traded up $3.07 during trading on Wednesday, reaching $26.06. The company had a trading volume of 8,680,840 shares, compared to its average volume of 4,940,691. Elanco Animal Health has a 12-month low of $10.75 and a 12-month high of $27.72. The stock’s 50 day moving average price is $23.82 and its two-hundred day moving average price is $23.29. The firm has a market capitalization of $12.95 billion, a price-to-earnings ratio of -54.33, a PEG ratio of 2.87 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.08 and a current ratio of 2.17.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same period in the previous year, the firm earned $0.37 earnings per share. Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, equities analysts expect that Elanco Animal Health will post 1.03 earnings per share for the current fiscal year.

More Elanco Animal Health News

Here are the key news stories impacting Elanco Animal Health this week:

• Positive Sentiment: Q1 results beat consensus — Elanco reported adjusted EPS of $0.40 and revenue of $1.371B (≈+15% y/y), topping estimates and showing organic growth and margin improvement. Read More.
• Positive Sentiment: Raised full‑year outlook — Management lifted FY 2026 guidance to $5.01–$5.085B revenue, adjusted EBITDA to $975M–$1.005B and adjusted EPS to $1.03–$1.09, and raised its innovation revenue target to $1.2B. These upgrades signal confidence in growth and cash generation. Read More.
• Positive Sentiment: Operational momentum — Adjusted EBITDA margin (24.5%), adjusted EPS and an intention to improve year‑end net leverage to ~3.0–3.2x suggest improving profitability and balance‑sheet focus. Read More.
• Neutral Sentiment: Q2 guide slightly soft vs. Street — Elanco gave Q2 EPS guidance of $0.250–$0.285 vs. a ~$0.29 consensus; revenue guidance for the quarter is roughly in line. This tempers upside near term but may reflect conservatism. Read More.
• Neutral Sentiment: Analyst sentiment steady — Coverage shows an average rating around “Moderate Buy,” indicating continued analyst support but not a consensus of strong upgrades. Read More.
• Negative Sentiment: Leverage and profitability caveats — Although targets were improved, adjusted net leverage remains elevated (reported ~3.5x) and GAAP metrics show mixed results; investors should watch cash‑flow and deleveraging execution. Read More.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ELAN. NewEdge Advisors LLC boosted its stake in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares during the period. Uniplan Investment Counsel Inc. purchased a new position in shares of Elanco Animal Health in the fourth quarter valued at $41,000. Geneos Wealth Management Inc. boosted its stake in shares of Elanco Animal Health by 53.7% in the second quarter. Geneos Wealth Management Inc. now owns 5,954 shares of the company’s stock valued at $85,000 after purchasing an additional 2,080 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Elanco Animal Health by 26.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,379 shares of the company’s stock valued at $91,000 after purchasing an additional 1,332 shares during the period. Finally, UMB Bank n.a. boosted its stake in shares of Elanco Animal Health by 31.9% in the fourth quarter. UMB Bank n.a. now owns 5,609 shares of the company’s stock valued at $127,000 after purchasing an additional 1,358 shares during the period. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.